Hi Smokey, good to see you again but I have to take issue with your notion that the deal was 30% of the company for $5M. Firstly, the second tranche of shares could attract a high price if an increase in the share price can be sustained. This mean that the $5M is the minimum price that NantVentures will pay. More importantly, we are getting a Pll drug to develop at no cost to us. To get the drug through the pre-clinical and Pl stages would have cost NantWorks at least $12-15M, even if the trial was a small trial. We get that research for free and so, when evaluating the deal, the cost of the early development must be included - either in whole or at least a significant part of it. When you add these figures together, you see that the value of the deal was greater than our market cap before the deal. How is that not a good deal? How have shareholders been robbed?
BLT Price at posting:
12.0¢ Sentiment: None Disclosure: Held
